Home Alzheimer’s Disease Adjuvant Sequential RT More Effective Than Concurrent RT or RT Alone for...

Adjuvant Sequential RT More Effective Than Concurrent RT or RT Alone for Patients with Cervical Cancer Following Hysterectomy

Sequential chemoradiation (SCRT) resulted in a higher disease-free survival (DFS) rate and lower risk of cancer death versus concurrent chemoradiation (CCRT) or radiation (RT) alone after surgery among women with early-stage cervical cancer, according to results from the randomized phase 3 STARS clinical trial (NCT00806117) which evaluated the 3 treatment modalities in a postoperative adjuvant treatment setting.

These study results, published in JAMA Oncology, support the use of SCRT as a preferred adjuvant treatment following radical hysterectomy for patients with early-stage cervical cancer.

“All of the findings together suggest that SCRT could be the most effective method among current adjuvant treatments for early-stage cervical cancer,” wrote the study authors, who were led by He Huang, MD.

In this multicenter, open-label trial, patients with FIGO (International Federation of…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...

Recent Comments